Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
NCT06225505

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

Led by Institut Curie · Updated on 2026-01-22

450

Participants Needed

13

Research Sites

290 weeks

Total Duration

On this page

Sponsors

I

Institut Curie

Lead Sponsor

N

National Research Agency, France

Collaborating Sponsor

AI-Summary

What this Trial Is About

CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept(1) to assess the clinical utility of ctDNA monitoring combined with 68Ga-FAPI-46-PET-CT imaging upon ctDNA detection for the surveillance of patients with a non-metastatic TNBC at high risk of relapse. The study has two steps. In Step 1, patients who have completed the treatments for a localized TNBC will undergo ctDNA monitoring every \~4 months (± 2 weeks). In Step 2, patients for whom ctDNA will be detected will then be randomized between an observation arm, in which monitoring will continue until the detection of a clinical relapse, and an experimental arm, in which the ctDNA detection will be revealed to both the patient and the clinician: patients will then undergo a 18F-FDG PET-CT and a 68Ga-FAPI-46-PET-CT, in addition to whatever workup the investigator will deem necessary.

CONDITIONS

Official Title

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed a written informed consent before joining the study
  • Female patients aged 18 years or older
  • Diagnosed with non-metastatic triple negative breast cancer (ER & PR <10%, HER2-negative)
  • Underwent surgery with curative intent for TNBC between 3 to 9 months before joining
  • Started any indicated adjuvant therapy at least 12 weeks before inclusion
  • High-risk primary tumor defined by lack of complete response after neoadjuvant chemotherapy, or stage IIB-III, or any loco-regional relapse after prior curative TNBC treatment
  • No signs of local or distant relapse
  • Performance status less than 2
  • Available tumor tissue sample with more than 10% cellularity
  • Able to follow study procedures
  • Covered by health insurance
Not Eligible

You will not qualify if you...

  • Any uncontrolled disease or medical condition interfering with trial procedures
  • Male participants
  • Altered mental status or psychiatric disorder preventing valid consent
  • Difficulty undergoing trial procedures due to geographic, social, or psychological reasons
  • Person deprived of liberty or under guardianship
  • History of other primary cancers except basal cell carcinoma, in situ carcinoma treated curatively, or stage I-II malignancies treated curatively with no active disease in last 5 years
  • Clinical or radiological metastatic relapse before molecular relapse detection in randomization step

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

Sainte-Catherine Institut du Caner Avignon-Provence

Avignon, France, 84918

Not Yet Recruiting

2

Institut Bergonié

Bordeaux, France, 33000

Not Yet Recruiting

3

Centre Jean Perrin

Clermont-Ferrand, France, 63011

Not Yet Recruiting

4

Centre Leon Bérard

Lyon, France, 69008

Not Yet Recruiting

5

Institut Paoli-Calmettes

Marseille, France, 13009

Not Yet Recruiting

6

Institut du cancer de Montpellier

Montpellier, France, 34298

Not Yet Recruiting

7

CHU Nîmes

Nîmes, France, 30900

Not Yet Recruiting

8

Hôpital Saint-Louis

Paris, France, 75010

Not Yet Recruiting

9

Hôpital Tenon

Paris, France, 75020

Not Yet Recruiting

10

Centre Eugène Marquis

Rennes, France, 35000

Not Yet Recruiting

11

Institut Curie

Saint-Cloud, France, 92340

Actively Recruiting

12

ONCOPOLE Claudius Regaud

Toulouse, France, 31059

Not Yet Recruiting

13

Institut de cancérologie de Lorraine

Vandœuvre-lès-Nancy, France, 54519

Not Yet Recruiting

Loading map...

Research Team

A

Anne-Claire COYNE

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here